Merck & Co Inc (MRK) Files 10-K for the Fiscal Year Ended on December 31, 2019

Author's Avatar
Feb 27, 2020
Article's Main Image

Merck & Co Inc (MRK, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. Merck & Co Inc has a market cap of $207.5 billion; its shares were traded at around $81.50 with a P/E ratio of 21.39 and P/S ratio of 4.60. The dividend yield of Merck & Co Inc stocks is 2.77%. GuruFocus rated Merck & Co Inc the business predictability rank of 2.5-star.

For the last quarter Merck & Co Inc reported a revenue of $11.9 billion, compared with the revenue of $11 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $46.8 billion, an increase of 10.7% from last year. For the complete 30-year financial data, please go here.. For the last five years Merck & Co Inc had an average revenue growth rate of 2.1% a year.

The reported diluted earnings per share was $3.81 for the year, an increase of 64.2% from previous year. Over the last five years Merck & Co Inc had an EPS growth rate of 1.1% a year. The Merck & Co Inc enjoyed an operating margin of 26.13%, compared with the operating margin of 21.12% a year before. The 10-year historical median operating margin of Merck & Co Inc is 17.18%. The profitability rank of the company is 8 (out of 10).

At the current stock price of $81.50, Merck & Co Inc is traded at 22.7% premium to its historical median P/S valuation band of $66.44. The P/S ratio of the stock is 4.60, while the historical median P/S ratio is 3.76. The intrinsic value of the stock is $40.77 a share, according to GuruFocus DCF Calculator. The stock gained 1.81% during the past 12 months.

For the complete 20-year historical financial data of MRK, click here.